Abstract
Historical progress in medicine can be charted along the lines of technical innovations that have visualized the invisible. One hundred years ago, Alois Alzheimer exploited newly developed histological stains to visualize his eponymonous disease in dead tissue under the microscope. Now, as we are entering the second century of Alzheimers disease research, technical innovation has endowed us with a range of in vivo imaging techniques that promise to visualize Alzheimer disease in living people. The earliest stage of Alzheimers disease is characterized by cell-sickness, not cell-death, and can occur before the deposition of amyloid plaques or neurofibrillary tangles. In principle, functional imaging techniques might be able to detect this early stage of the disease, a stage that was invisible to Alzheimer himself. Here, we will first define the neurobiological meaning of function and then review the different approaches that measure brain dysfunction in Alzheimer disease.
Keywords: Cerebral Blood Flow, SPECT, Deoxyhemoglobin, Glucose Uptake, synaptic strength, MRI
Current Alzheimer Research
Title: Imaging the Earliest Stages of Alzheimers Disease
Volume: 3 Issue: 5
Author(s): William Wu and Scott A. Small
Affiliation:
Keywords: Cerebral Blood Flow, SPECT, Deoxyhemoglobin, Glucose Uptake, synaptic strength, MRI
Abstract: Historical progress in medicine can be charted along the lines of technical innovations that have visualized the invisible. One hundred years ago, Alois Alzheimer exploited newly developed histological stains to visualize his eponymonous disease in dead tissue under the microscope. Now, as we are entering the second century of Alzheimers disease research, technical innovation has endowed us with a range of in vivo imaging techniques that promise to visualize Alzheimer disease in living people. The earliest stage of Alzheimers disease is characterized by cell-sickness, not cell-death, and can occur before the deposition of amyloid plaques or neurofibrillary tangles. In principle, functional imaging techniques might be able to detect this early stage of the disease, a stage that was invisible to Alzheimer himself. Here, we will first define the neurobiological meaning of function and then review the different approaches that measure brain dysfunction in Alzheimer disease.
Export Options
About this article
Cite this article as:
Wu William and Small A. Scott, Imaging the Earliest Stages of Alzheimers Disease, Current Alzheimer Research 2006; 3 (5) . https://dx.doi.org/10.2174/156720506779025161
DOI https://dx.doi.org/10.2174/156720506779025161 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Use of Proteomics to Study Infectious Diseases
Infectious Disorders - Drug Targets Bacterial Operational Taxonomic Units Replace the Interactive Roles of Other Operational Taxonomic Units Under Strong Environmental Changes
Current Genomics Potential Drugs Targeting Microglia: Current Knowledge and Future Prospects
CNS & Neurological Disorders - Drug Targets Synthesis of Imidazo[1,2-b]pyridazine Comprised Piperazine, Morpholine Derivatives as Potent Antimycobacterial Agents with In Vivo Locomotor Activity
Anti-Infective Agents In Vitro and In Vivo Modeling of Tuberculosis Drugs and its Impact on Optimization of Doses and Regimens
Current Pharmaceutical Design In Vitro Models of the Blood-Brain Barrier: When to Use Which?
Current Medicinal Chemistry - Central Nervous System Agents New Perspectives in the Pharmacological Treatment of Non-Melanoma Skin Cancer
Current Drug Targets Neuroglial Roots of Neurodegenerative Diseases: Therapeutic Potential of Palmitoylethanolamide in Models of Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Targeting Heme Oxygenase-1 for Neuroprotection and Neuroinflammation in Neurodegenerative Diseases
Current Drug Targets Non-Steroidal Anti-Inflammatory Drugs used as a Treatment Modality in Subarachnoid Hemorrhage
Current Drug Safety Role of Platelet Signaling in Thrombus Stabilization: Potential Therapeutic Implications
Current Signal Transduction Therapy The Multifaceted Activities of Mammalian Defensins
Current Pharmaceutical Design Can Mycobacterial Genomics Generate Novel Targets as Speed-Breakers Against the Race for Drug Resistance
Current Pharmaceutical Design A Review of Epidemic Models Related to Meteorological Factors
Current Bioinformatics New Vaccines and Delivery Strategies for Adult Immunization
Current Immunology Reviews (Discontinued) Peroxisome Proliferator-Activated Receptor-α Activation Protects Brain Capillary Endothelial Cells from Oxygen-Glucose Deprivation-Induced Hyperpermeability in the Blood-Brain Barrier
Current Neurovascular Research The Rise of Carbapenem-Resistant Acinetobacter baumannii
Current Pharmaceutical Design In-Vivo Gene Delivery by Sonoporation: Recent Progress and Prospects
Current Gene Therapy Fish and Apoptosis: Studies in Disease and Pharmaceutical Design
Current Pharmaceutical Design Therapeutic Targets for the Prevention of Type 1 Diabetes Mellitus
Current Drug Targets - Immune, Endocrine & Metabolic Disorders